These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from competitors and generate strong returns for shareholders
But if investing a company with a strong moat is a great idea, wouldn't it be even better to buy one that has no direct competition at all? Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR), and Acadia Pharmaceuticals (NASDAQ: ACAD).
Image source: Getty Images.
Source: Fool.com
Acadia Pharmaceuticals Stock
€25.04
-0.950%
With 27 Buy predictions and not a single Sell prediction Acadia Pharmaceuticals is an absolute favorite of our community.
As a result the target price of 29 € shows a slightly positive potential of 15.81% compared to the current price of 25.04 € for Acadia Pharmaceuticals.
